The HER2-specific tyrosine kinase inhibitor zongertinib was well tolerated and demonstrated promising efficacy in patients with HER2 mutation-positive non-small cell lung cancer, meeting the primary endpoint of the Beamion LUNG-1 Phase Ib Cohort 1 study, according to research presented today at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.
Eylea drugmaker Regeneron launches eye disease awareness effort with actor and dancer Debbie Allen
Regeneron wants older adults to start doing monthly vision checks at home, and it’s enlisting actor and dancer Debbie Allen to help lead the way.